Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma (SEP) for the exclusive distribution of Mitocin®/Mitem® (mitomycin) - 22 October 2014
Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma (SEP) for the exclusive distribution of Mitocin®/Mitem® (mitomycin) to the Caribbean, Egypt, Kuwait, Iran, Saudi Arabia, UAE, Kenya, Seychelles, Uganda, Zimbabwe, Chile, Denmark, Greece, Ireland, Norway and Sweden.
Masters has 30 years experience in the ethical and compliant supply of drugs to countries where an unmet need for the medication exists. Our regulatory knowledge, licensure and logistics capabilities will ensure that patients requiring treatment with Mitocin®/Mitem® (mitomycin) have access to this important medication.
Rakesh Tailor, Speciality European Pharma’s General Manager for Northern Europe said: Having worked with Masters for a number of years we are delighted to have cemented this partnership through formal agreement. This arrangement hopefully signals the continuum of a long and successful business relationship.
Mitocin®/Mitem® (mitomycin) is a cytotoxic medicine used in the treatment of a variety of cancers, including bladder cancer, and although the product has been on the market for many years it remains the treatment of choice for many patients with superficial risk bladder cancer.
Heather Gamble, Masters Business Marketing Director said: Entering into exclusive partnership with Specialty European Pharma allows us to focus our resources on the territories where we have been granted exclusive distribution, this will help to ensure medication reaches those patients requiring treatment with mitomycin.
In order to obtain access to Mitocin®/Mitem® (mitomycin) patients or healthcare professionals should contact:
Masters Speciality Pharma Email:
Phone: +44 (0)208 327 0900
Fax: +44 (0)208 327 0901